Indivior Raises EPS Forecast, Projects Modest Revenue Growth for FY2026
Indivior Pharmaceuticals reports stronger Q1 EPS, upbeat outlook, but modest revenue growth. Learn how strategic cost cuts boost shareholder value in a volatile market.
- Indivior Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read